Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - read this article along with other careers information, tips and advice on BioSpace
New data presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022, held Sept. 30-Oct. 3 in Washington, DC, shed light on the impact of an FDA-cleared blood volume analysis test to benefit patients with heart failure. During the HFSA Meeting, Daxor Corporation announced new data from multiple studies validating the benefits of the company’s BVA-100 blood test for patients with heart failure.
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.